Press Releases & Company News

2010 R&D Day: COSMO updates investors and analysts on progress and new developments in its R&D pipeline

See http://www.cosmopharmaceuticals.com/csm/ir/ for more information
The presentation in Zurich with dial in conference call begins at 10:00 a.m. CET

LAINATE (December 1, 2010) At Cosmo’s R&D day, Cosmo Pharmaceuticals S.p.A. (SIX: COPN) will present additional data from the recently concluded phase III Budesonide trial, and the progress of its development pipeline. Special attention will be given to the next steps on LMW Heparin, a new diagnostic using the MMX technology and the next steps in its novel new chemical entity for the topical treatment of acne, hirsutism and alopecia.

The following members of the Executive Management will be presenting:

Mauro Ajani, Chief Executive Officer and majority shareholder
Luigi Moro, Chief Scientific Officer
Chris Tanner, Chief Financial Officer

Mauro Ajani of Cosmo Pharmaceuticals, said, “Our R&D day will demonstrate the progress we have made in expanding our MMX platform. I am especially excited by our new diagnostic product and the progress we have made with our new skin molecule and will be pleased to share my views including the prospects of these initiatives”

Overview new disclosure:
First time discussion of Cosmo’s new diagnostic for ulcerative colitis and colon cancer and its financial prospects.

The R&D day is expected to end around 13:30 CET.

Dial-in details for the participation at today’s R&D day in Zurich are as follows:
+41 (0)91 610 56 00 (Europe)
+44 (0)203 059 58 62 (UK)
+1 (1)866 291 41 66 (USA - Toll-Free)

Presentation online available on http://www.cosmopharmaceuticals.com/csm/ir/

About Cosmo Pharmaceuticals
Cosmo is a speciality pharmaceutical company that aims to become a global leader in optimised therapies for selected gastrointestinal and topically treated skin disorders. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as ulcerative colitis and Crohn’s disease, and colon infections. Cosmo’s first MMX^® product that has reached the market is Lialda^® / Mezavant^® / Mesavancol^®, a treatment for IBD that is licensed globally to Giuliani and Shire Limited. Cosmo’s proprietary MMX^® technology is at the core of its product pipeline and was developed
from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the intestines. More information about Cosmo is available on the company’s website at www.cosmopharma.com.

COSMO CONTACT:
Dr. Chris Tanner, CFO & Head of Investor Relations
Tel: +39 331 5700 1679
Fax: +39 02 9333 7663
ctanner@cosmopharma.com

Cautionary Statement Regarding Forward Looking Statements
This report and other material being released by Cosmo herewith contains statements that constitute “forward looking statements” including but not limited to managements outlook for Cosmo’s pipeline development and financial performance and statements relating to the anticipated effect of transactions and strategic initiatives on Cosmo’s business and future development. While these forward looking statements represent Cosmo’s judgments and expectations concerning the matters therein described, a number of risks, uncertainties and other important factors could cause actual developments and results to differ from Cosmo’s expectations.

Most computers will open PDF documents automatically, but you may need to download Adobe Reader.